← All market reports

Neurology & CNS Market Research Reports 2026 — GCC & MENA Intelligence

Neurodegeneration (Alzheimer anti‑amyloid infusions contentious but expanding where MRI safety monitoring infrastructures exist ), MS high efficacy BCD clones (natalizumab, ocrelizumab, ofatumumab self‑injectable shifts ), epilepsy adjunct small molecules versus cannabidiol special programs, migraine CGRP monoclonals revolutionizing episodic burden, plus movement disorder adjuncts modulate prescribing concentration within electrophys‑equipped neurologist panels. Stroke thrombolysis/thrombectomy capacity skews tertiary city clusters affecting secondary prevention antithrombotic and statin ramps.